XtalPi enters partnership for small molecule therapy for GPCR target

XtalPi has entered a strategic partnership with a biopharmaceutical company to develop oral small-molecule therapeutics targeting a GPCR. XtalPi stands to receive further payments based on clinical and commercial milestones, as well as future royalties. XtalPi will use its structure-based drug design platform, integrating quantum physics, generative AI, and automated chemical synthesis. Credit: Wasan Tita / Shutterstock.com. XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR). The collaboration follows a successful pilot phase, where XtalPi’s integrated quantum physics and AI algorithms achieved…

Source: Pharmaceutical Technology